Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.6 USD | -2.20% | -0.83% | -19.01% |
12:07pm | North American Morning Briefing : More Tech -2- | DJ |
Apr. 24 | HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's enterprise value to sales, at 3.55 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.20% | 83.65B | B- | ||
+25.61% | 660B | C+ | ||
+22.53% | 562B | B | ||
-5.24% | 358B | C+ | ||
+16.49% | 322B | B- | ||
+8.28% | 297B | C+ | ||
+13.51% | 219B | B+ | ||
-9.65% | 196B | A+ | ||
+6.65% | 199B | B- | ||
-8.75% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GILD Stock
- Ratings Gilead Sciences, Inc.